Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
34 participants
INTERVENTIONAL
2022-02-28
2022-04-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Photoallergic Potential of 6% Bemotrizinol
NCT05254912
Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol
NCT05260359
Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study
NCT04355286
Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects
NCT04520217
Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream
NCT03892564
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Duplicate test sites on the back (each approximately 4 cm2) will be identified via use of body map demonstrating application sites. Test material will be applied to designated patches and affixed to both sides of the back. In addition, 2 sets of patches without test material will be applied on 2 sides of the back. One side will be designated for irradiation, and the other is used as a treated/non-irradiated, and non-treated/non- irradiated control.
Approximately 24 hours after application, the patches will be removed and the skin will be gently wiped. The Minimal Erythema Dose (MED) will be determined from the five UV-treated sub-sites and all of the test sites will be evaluated according to the erythema grading scale. For evaluation of phototoxicity, the sites are irradiated with 0.5 of the subject's MED (full spectrum wavelengths UVB 290-320 nm and UVA 320-400 nm) followed by 5 J/cm2 UVA (320-400nm) using a Schott WG-345 and UG11/1 mm filter to block UVB wavelength 290-320 nanometers. The sites designated for irradiation will be then irradiated with solar simulated light by 0.5 times an individual's MED followed by 5 J/cm2 UVA.
Statistical analysis will not be performed for this study. Investigational product safety will be determined through interpretation of the dermal evaluation scores. Treated and control sites will be examined at 24 and 48 hours post-irradiation and graded according to a scoring scale.
If a grade ≥2+ erythema is observed after patch removal on the site designated for irradiation, the site will not be irradiated, regardless of the dermal response of the non-irradiated site and the subjects will be discontinued by the Principal Investigator from the study. The dermal response will be followed up until resolution or until the end of the study.
Dermal scores will be reported for each site. Clinically significant reactions other than phototoxic reactions will be recorded and interpreted accordingly and the safety of the investigational product will be monitored by evaluating adverse event reporting. An adverse event is any untoward medical occurrence, whether or not it is considered clinical trial related, including death, experienced by a subject. An event may consist of a disease, an exacerbation of a pre-existing illness or condition, an occurrence of an intermittent illness or condition, a set of related symptoms or signs, or a single symptom or sign. Any subject that presents with a dermal reaction of 3+ or greater will be considered as an adverse event and documented accordingly.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phototoxicity evaluation of sunscreen oil with 6% BEMT (SU E 101413 85)
Assessment of the phototoxicity potential of sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer a test material (formulation: SU E 101413 85).
The phototoxic response of the investigational product: SU E 101413 85 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject.
Sunscreen oil with 6% Bemotrizinol
Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
Phototoxicity evaluation of sunscreen oil vehicle (SU E 101413 91)
Vehicle Control: Assessment of the phototoxicity potential of sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (formulation: SU E 101413 91).
The phototoxic response of the investigational product: SU E 101413 91 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject.
Sunscreen oil vehicle
Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
Phototoxicity evaluation of dispersion of 6% BEMT in petrolatum (SU E 101413 82)
Assessment of the phototoxicity potential of a dispersion of 6% BEMT (PARSOL® Shield) in petrolatum (formulation: SU E 101413 82).
The phototoxic response of the investigational product: SU E 101413 82 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject.
Dispersion of 6% BEMT in petrolatum
Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
Phototoxicity evaluation of petrolatum vehicle (SU-E-101413-83)
Vehicle Control: Assessment of the phototoxicity potential of petrolatum vehicle (SU-E-101413-83).
The phototoxic response of the investigational product: SU E 101413 83 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject.
Petrolatum vehicle
Petrolatum vehicle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sunscreen oil with 6% Bemotrizinol
Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
Sunscreen oil vehicle
Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
Dispersion of 6% BEMT in petrolatum
Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
Petrolatum vehicle
Petrolatum vehicle
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has a Fitzpatrick Skin Types I - III, based on the first 30 to 45 minutes of sun exposure after a winter season of no sun exposure according to the following criteria; I Always burns easily; never tans (sensitive) II Always burns easily; tans minimally (sensitive) III Burns moderately; tans gradually (normal)
3. Subject agrees to avoid excessive sun exposure of the test sites and to refrain from visits to tanning salons during the course of this study;
4. Subject does not exhibit any skin diseases or abnormalities which might be confused with a skin reaction from the test material;
5. Subject agrees not to introduce any new cosmetic or toiletry products during the study;
6. Subject agrees to refrain from getting patches wet and from scrubbing or washing the test area with soap or applying powders, lotions or personal care products to the area during the course of the study;
7. Subject is dependable and able to follow directions as outlined in the protocol and anticipates being available for all study visits;
8. Subject is willing to participate in all study evaluations;
9. Subject is in generally good health and has a current Panelist Profile Form on file at CRL;
10. Subject has completed a HIPAA Authorization Form in conformance with 45 CFR Parts 160 and 164;
11. Subject understands and is willing to sign an Informed Consent Form in conformance with 21 CFR Part 50: "Protection of Human Subjects."
Exclusion Criteria
2. Subjects with a prior history of phototoxic or photoallergic reactions or those taking medication which might produce an abnormal response to sunlight;
3. Subject has received treatment with sympathomimetics, antihistamines, vasoconstrictors, non-steroidal anti-inflammatory agents, and/or systemic or topical corticosteroids within one week prior to initiation of the study;
4. Subject has a history of acute or chronic dermatologic, medical, and/or physical conditions which would preclude application of the test material and/or could influence the outcome of the study;
5. Subject is under treatment for a skin and/or systemic bacterial infection;
6. Subject reports a history of allergies to tape adhesives;
7. Subject is currently taking certain medications which, in the opinion of the Principal Investigator, may interfere with the study;
8. Subject has known allergies to sunscreen, skin treatment products or cosmetics, toiletries, and/or topical drugs;
9. Subject has a known communicable disease (e.g., HIV, sexually transmitted diseases, Hepatitis B, Hepatitis C, etc.);
10. Subject has insulin-dependent diabetes;
11. Subject has a history of cancer;
12. Subject is currently taking certain medications which, in the opinion of the Principal Investigator, may interfere with the study;
13. Subject exhibits sunburn, suntan, uneven skin tone, blemishes, moles or excess hair in the test site area.
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DSM Nutritional Products, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rolf Schutz, PhD
Role: STUDY_DIRECTOR
DSM Nutritional Products, Inc.
Gladys Osis, MT
Role: PRINCIPAL_INVESTIGATOR
Eurofins CRL Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eurofins | CRL, Inc.
Piscataway, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DSM PT 2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.